Buyout Buzz Boosts Fibrocell Science Stock

FCSC is eyeing its highest close in over a year

Digital Content Manager
Sep 13, 2019 at 9:31 AM
facebook twitter linkedin

The shares of Fibrocell Science Inc (NASDAQ:FCSC) are booming on a buyout deal from Castle Creek Pharmaceutical. The privately held company has agreed to acquire Fibrocell Science for about $63.3 million. In response, the penny stock has tacked on 60.1% to trade at $2.93, eyeing its highest close in over a year. 

On the charts, FCSC has been trading between $1.70 and $2.10 for the better part of 2019, with two brief breakouts capped by the stock's 320-day moving average in late March and early April. The stock is trading well atop this trendline today, though it's still well below the all-time high of $862.50, hit back in 2009. 

Only two analysts follow the stock, but both in coverage are extremely bullish, giving FCSC a "buy" or better rating. What's more, the 12-month consensus price target of $15 hasn't been touched by the equity in nearly two years. 

Interestingly enough, short interest just dropped to a one-year low, down 30% in the last two reporting periods. The 518,836 shares sold short still account for a healthy 5.3% of FCSC's available float, however, and would take over two weeks to cover, at the security's average pace of trading. 


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners